Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Is CIDP Hereditary or Contagious? Passing It to Children

At a Glance

Typical CIDP happens when the immune system attacks the protective covering of nerves; it is not an infection and is usually not passed from parent to child. Atypical features or family history may warrant evaluation for a nerve condition that runs in families.

Typical chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated condition [1][2][3]. It is not contagious, and you cannot catch it from or pass it to anyone else. It is also generally not considered a hereditary disease, meaning the vast majority of people with CIDP will not pass the condition directly to their children [4][5].

However, patients often worry about passing their condition to their children because CIDP can sometimes be confused with inherited neuropathies, such as Charcot-Marie-Tooth (CMT) disease, which are passed down in families [6][7].

Not a Contagious Illness

CIDP occurs when your immune system mistakenly attacks the myelin sheath (the protective coating around your peripheral nerves) [1][2][3]. A viral infection or flu-like illness might occasionally trigger an immune response or cause symptoms to worsen in someone who already has CIDP [8]. While that initial viral illness may have been contagious, CIDP itself is not an infection [1][8]. You cannot transmit CIDP to your family members, friends, or caregivers by touching, coughing, or living in the same house.

CIDP vs. Hereditary Neuropathies

Because CIDP and hereditary neuropathies both cause nerve damage, they can look similar on the surface. Sometimes, a person diagnosed with CIDP may actually have an inherited neuropathy like Charcot-Marie-Tooth (CMT) disease or hereditary neuropathy with liability to pressure palsies (HNPP) [6][7].

If your condition is indeed an inherited neuropathy, there is a risk of passing it to your children. This is why getting an accurate diagnosis is crucial for family planning and understanding your children’s risk [9][7][10].

Certain features may raise suspicion that a neuropathy is inherited rather than acquired. However, these are clues, not strict diagnostic rules:

  • Age of onset: Inherited conditions often begin in childhood or early adulthood [7][9].
  • Pacing of symptoms: Inherited neuropathies usually progress very slowly over many years. Typical CIDP usually progresses over at least eight weeks, though some acute-onset variants can worsen more rapidly [11][7].
  • Physical signs: Longstanding physical changes like pes cavus (very high arches), hammertoes, or scoliosis (curved spine) are common in inherited neuropathies, but they can also develop in any long-standing neuropathy [7][9][12].
  • Family history: Having biological relatives with neuropathy, foot deformities, or a history of frequent nerve palsies is a major clue [7][9][12]. However, the absence of a known family history does not rule out an inherited condition, as some are inherited recessively or occur from new genetic changes [7][9].
  • Treatment response: A lack of response to standard CIDP immunotherapies (such as IVIG, corticosteroids, or plasma exchange) should prompt a clinical reassessment of both the diagnosis and treatment [7][9][12]. Non-response does not automatically mean you have an inherited condition; it could also reflect severe nerve damage or the need for a different therapy. Never stop or change your immunotherapy without consulting your neurologist.

Electrodiagnostic tests—including nerve conduction studies (NCS) and electromyography (EMG)—also provide important clues. Acquired demyelination (like in CIDP) often produces non-uniform slowing, “conduction block” (signals stopping abruptly), or temporal dispersion [13][14][7]. Inherited conditions tend to show more uniform, diffuse nerve slowing, but there is significant overlap, and findings can vary [14][7]. Because test results can be complex, they must be interpreted by an experienced neuromuscular clinician.

When to Consider Genetic Testing and Counseling

If you have a confirmed diagnosis of typical CIDP that responds well to treatment, genetic testing is generally not necessary, and you do not need to worry about directly passing the disease to your children [4][5].

However, your doctor may suggest assessing whether a known hereditary neuropathy is likely if your condition is atypical, does not respond to treatment, or if you have strong family history clues [15][7][16].

If genetic testing is considered, a genetic counselor can help guide the process. Genetic testing can identify specific gene mutations (such as in the PMP22 gene associated with CMT and HNPP) [6][7]. Keep in mind that a negative genetic test cannot completely exclude all inherited neuropathies. If a specific genetic cause is found, a counselor can help you understand the inheritance pattern, what it means for your reproductive planning, and discuss medication safety during pregnancy with your care team [9][7][10].

Common questions in this guide

Can someone with CIDP pass it on to their children?
Typical CIDP is acquired when the immune system attacks the protective covering of peripheral nerves, so it is generally not passed directly from parent to child. If the diagnosis is actually an inherited neuropathy, such as Charcot-Marie-Tooth disease, the chance of passing it on can be different.
Is CIDP contagious through close contact?
No. CIDP is not an infection and cannot be spread by touching, coughing, sharing a home, or caring for someone. A separate viral illness may sometimes trigger immune symptoms, but the virus—not CIDP—would be contagious.
How do doctors distinguish CIDP from an inherited nerve disorder?
They consider when symptoms began, how quickly they progressed, physical signs, family history, and response to treatment. Electrical tests of nerve and muscle function, including nerve conduction studies and electromyography, can provide clues, but results may overlap. Genetic testing may be considered when the history or test results suggest a condition that runs in families.
When might genetic testing be useful for someone diagnosed with CIDP?
It may be useful when symptoms began unusually early, progressed very slowly, there is a strong family history, or CIDP treatment has not helped as expected. A negative result does not rule out every inherited neuropathy, so results should be interpreted with a neurologist or genetic counselor.
What can a genetic counselor explain about having children?
A genetic counselor can explain what a confirmed gene change means, how a nerve condition may be inherited, and what it could mean for children. They can also help with reproductive planning and coordinate questions about medication safety during pregnancy with your care team.
Does poor response to CIDP treatment prove that the condition is inherited?
No. Lack of improvement can lead to a review of the diagnosis and treatment plan but may also reflect severe nerve damage or the need for a different therapy. Do not stop or change immunotherapy without speaking with your neurologist.

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies.

    Reynolds J, Sachs G, Stavros K

    Rhode Island medical journal (2013) 2016; (99(12)):32-35.

    PMID: 27902997
  2. 2

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management.

    Chen Y, Tang X

    Frontiers in immunology 2022; (13()):890142 doi:10.3389/fimmu.2022.890142.

    PMID: 35860284
  3. 3

    Myokymia in a Patient with Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Gangula PKRP, Samarla PK, Krishnasamy MJ, et al.

    The Journal of the Association of Physicians of India 2023; (71(12)):100-101 doi:10.59556/japi.71.0408.

    PMID: 38736063
  4. 4

    Identification of rare variants in the FBXO38 gene of patients with chronic inflammatory demyelinating polyradiculoneuropathy.

    Pegat A, Chanson JB, Lozeron P, et al.

    Journal of neuroimmunology 2024; (392()):578381 doi:10.1016/j.jneuroim.2024.578381.

    PMID: 38823119
  5. 5

    Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.

    Wang Z, Zhou X, Zhao N, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(6)):2223-2233 doi:10.1007/s10072-021-05220-3.

    PMID: 33782779
  6. 6

    Hereditary Neuropathy with Liability to Pressure Palsies Mimicking a Chronic Inflammatory Demyelinating Polyneuropathy Variant: A Case Report Highlighting Diagnostic Challenges.

    Yamamoto M, Hatanaka Y, Kaida K

    Internal medicine (Tokyo, Japan) 2026; (65(9)):1302-1306 doi:10.2169/internalmedicine.5771-25.

    PMID: 41062314
  7. 7

    Charcot-Marie-Tooth type 4 C misdiagnosed as CIDP: electrodiagnostic pitfalls and genetic confirmation.

    Okhovat AA, Shahriyari H, Ghasemi A, et al.

    Neurogenetics 2026; (27(1)).

    PMID: 42377577
  8. 8

    Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Ueda J, Yoshimura H, Kohara N

    Internal medicine (Tokyo, Japan) 2018; (57(18)):2723-2726 doi:10.2169/internalmedicine.0588-17.

    PMID: 29709940
  9. 9

    Genetic neuropathies presenting with CIDP-like features in childhood.

    Fernandez-Garcia MA, Stettner GM, Kinali M, et al.

    Neuromuscular disorders : NMD 2021; (31(2)):113-122 doi:10.1016/j.nmd.2020.11.013.

    PMID: 33386210
  10. 10

    Heterogeneous Presentation of Hereditary Neuropathy With Liability to Pressure Palsies: Clinical and Electrodiagnostic Findings in Three Patients.

    Shields LB, Iyer VG, Zhang YP, Shields CB

    Cureus 2022; (14(12)):e32296 doi:10.7759/cureus.32296.

    PMID: 36628033
  11. 11

    Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

    Allen JA, Gelinas DF, Freimer M, et al.

    Journal of the neurological sciences 2020; (408()):116497 doi:10.1016/j.jns.2019.116497.

    PMID: 31765922
  12. 12

    Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses.

    Rajabally YA, Adams D, Latour P, Attarian S

    Journal of neurology, neurosurgery, and psychiatry 2016; (87(10)):1051-60 doi:10.1136/jnnp-2015-310835.

    PMID: 27010614
  13. 13

    [Phenotypes of Charcot-Marie-Tooth Syndrome and Differential Diagnosis Focused in Inflammatory Neuropathies].

    Iijima M

    Brain and nerve = Shinkei kenkyu no shinpo 2016; (68(1)):31-42 doi:10.11477/mf.1416200343.

    PMID: 26764297
  14. 14

    Are electrophysiological criteria useful in distinguishing childhood demyelinating neuropathies?

    Potulska-Chromik A, Ryniewicz B, Aragon-Gawinska K, et al.

    Journal of the peripheral nervous system : JPNS 2016; (21(1)):22-6 doi:10.1111/jns.12152.

    PMID: 26663344
  15. 15

    Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study.

    Hauw F, Fargeot G, Adams D, et al.

    European journal of neurology 2021; (28(9)):2846-2854 doi:10.1111/ene.14950.

    PMID: 34060689
  16. 16

    Pediatric Chronic Inflammatory Demyelinating Polyneuropathy: Challenges in Diagnosis and Therapeutic Strategies.

    Alawneh I, Alenizi A, Paiz F, et al.

    Paediatric drugs 2024; (26(6)):709-717 doi:10.1007/s40272-024-00646-6.

    PMID: 39192168

This page is for informational purposes only and does not constitute medical advice. Your neurologist and, when appropriate, a genetic counselor can help clarify your diagnosis and discuss family planning.